David Nierengarten
#85 out of 1697 analysts
Wedbush
Automatically Tracked
Analyst ratings are aggregated from multiple third-party sources and may be inaccurate, incomplete, or outdated. All ratings remain the sole responsibility of their original providers. Rankings are based on the 3-year performance of a simulated $100,000 account trading on analyst ratings data.
Gain and growth charts are calculated per selected timeframe:
106.83%
Gain +1.33%
Monthly
0.93%
Yearly
11.77%
Drawdown
45.31%
$289,953.11
Equity
Holdings
$114,550.62
Cash
$175,402.49
Investment
$153,272.58
$189,953.09
Profit +$3,817.52
Realized
$228,675.05
Unrealized
-$38,721.96
Dividends
$0
$175,402.49
Cash
Deposits
$100,000.02
Withdrawals
$0
Commissions
$0
Goals
Avg. 0% completed goals
Today
Compared To Yesterday
Gain
1.33%
Profit
$3,817.52
Win %
0%
This Week
Compared To Last Week
Gain
-2.09%
Profit
-$6,201.57
Win %
0%
This Month
Compared to last month
Gain
-5.58%
Profit
-$17,119.55
Win %
0%
This Year
Compared to last year
Gain
16.25%
Profit
$40,531.24
Win %
66%
TCRX TScan Therapeutics Inc.
+13.53%
+$1,470.8 
BEAM Beam Therapeutics Inc.
+4.38%
+$700.15 
ARGX argenx SE American Depositary Receipt
+4.09%
+$551.61 
IRON Disc Medicine Inc.
+3.74%
+$447.8 
BCAX Bicara Therapeutics Inc.
+1.84%
+$229.74 
DMRA Damora Therapeutics, Inc.
+1.71%
+$204.6 
BBOT BridgeBio Oncology Therapeutics, Inc.
+1.55%
+$113.45 
IMNM Immunome Inc.
+0.76%
+$84.76 
SYRE Spyre Therapeutics, Inc.
+0.23%
+$35.26 No Data
Events
Loading...
Dividends
Dividend Analysis
Loading...
No Data
| Trades 1268 | Longs Won 692/1232 56% | Profit Factor 1.41 |
| Profitability | Shorts Won 21/36 58% | Standard Deviation $2,320.97 |
| Average Win $911.31 | Best Trade (Jul 12) $40,879.3 | Sharpe Ratio -165.38 |
| Average Loss -$828.48 | Worst Trade (Mar 25) -$33,146.02 | Z-Score -10.08 (100%) |
| Commissions $0 | Avg. Trade Length 2m 3d | Expectancy $149.81 |
| Loss Size | 100% | 90% | 80% | 70% | 60% | 50% | 40% | 30% | 20% | 10% |
| Probability of Loss | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | <0.01% | 0.03% | 0.32% | 2.77% | 18.39% |
| Consecutive Losing Trades | 350 | 315 | 280 | 245 | 210 | 175 | 140 | 105 | 70 | 35 |
Hover over the desired column for a detailed explanation.
Returns
Overall, Monthly| Symbol | Quantity | Cost | Value | Comm. | Profit ($) | Gain (%) | Change |
|---|---|---|---|---|---|---|---|
| ARGX argenx SE American Depositary Receipt | 16.48 | $17,030.29 | $14,033.68 | - | -$2,996.61 | -17.6% | +4.091% |
| BBOT BridgeBio Oncology Therapeutics, Inc. | 2,521.14 | $17,030.29 | $7,437.36 | - | -$9,592.93 | -56.33% | +1.549% |
| BCAX Bicara Therapeutics Inc. | 720.4 | $17,030.29 | $12,721.49 | - | -$4,308.8 | -25.3% | +1.839% |
| BEAM Beam Therapeutics Inc. | 676.48 | $17,030.29 | $16,698.81 | - | -$331.48 | -1.95% | +4.376% |
| DMRA Damora Therapeutics, Inc. | 648.28 | $17,030.29 | $12,152.38 | - | -$4,877.91 | -28.64% | +1.712% |
| IMNM Immunome Inc. | 652 | $17,030.29 | $11,299.19 | - | -$5,731.1 | -33.65% | +0.756% |
| IRON Disc Medicine Inc. | 214.95 | $17,030.29 | $12,428.97 | - | -$4,601.32 | -27.02% | +3.738% |
| SYRE Spyre Therapeutics, Inc. | 195.91 | $17,030.29 | $15,439.51 | - | -$1,590.78 | -9.34% | +0.229% |
| TCRX TScan Therapeutics Inc. | 51,606.93 | $17,030.29 | $12,339.22 | - | -$4,691.07 | -27.55% | +13.533% |
No Data
Option values are updated at end of day.
No Data
No Data
Option values are updated at end of day.
No Data
No Data
No Data
No Data
2026 © Marketlog. All Rights Reserved.
